Molecular pathology of Wilson’s disease: A brief

Slides:



Advertisements
Similar presentations
SODIUM – POTASSIUM PUMP  Inside Cell:  High K + / Low Na + relative to extracellular medium  The sodium potassium pump uses energy to generate and.
Advertisements

04.10 The Sodium-Potassium Pump
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Vitamin D for your patients with chronic hepatitis C?
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 125, Issue 6, Pages (December 2003)
Diverse Functional Properties of Wilson Disease ATP7B Variants
Volume 52, Issue 3, Pages (March 2010)
Structural and functional hepatocyte polarity and liver disease
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Valérie Vilgrain, Bernard E. Van Beers, Catherine M. Pastor 
Iron and the liver: Update 2008
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Copper Deficiency Myelopathy (Human Swayback)
Living donor liver transplantation: is the hype over?
F. Gisou van der Goot, Jean Gruenberg  Developmental Cell 
The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions  Anne Vankeerberghen, Harry Cuppens, Jean-Jacques.
Human serum albumin, systemic inflammation, and cirrhosis
Volume 131, Issue 1, Pages (July 2006)
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Wilson’s Disease Clinical Gastroenterology and Hepatology
ChREBP in NASH – A liver transcription factor comes in from the cold
Cholera 12 The American Journal of Medicine
Hepatitis C core protein – The “core” of immune deception?
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Volume 134, Issue 4, Pages (April 2008)
Function of Copper Transporters
Mechanisms of iron hepatotoxicity
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Aloysious D. Aravinthan, Graeme J.M. Alexander  Journal of Hepatology 
Control of iron metabolism – Lessons from neonatal hemochromatosis
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Volume 62, Issue 3, Pages (March 2015)
Advancing hepatitis B virus entry inhibitors
Autophagy in the liver Journal of Hepatology
Volume 52, Issue 2, Pages (February 2010)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Age and liver transplantation
Wilson Disease Mayo Clinic Proceedings
Vitamin D for your patients with chronic hepatitis C?
Molecular-Dynamics Simulations of the ATP/apo State of a Multidrug ATP-Binding Cassette Transporter Provide a Structural and Mechanistic Basis for the.
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
The potential of induced pluripotent stem cell derived hepatocytes
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Copper Transporters: CTR1, CTR2, ATP7A, & ATP7B
Ann L. Hubbard, Lelita T. Braiterman  Gastroenterology 
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Volume 57, Issue 3, Pages (March 2000)
Genetics of hepatocellular carcinoma: The next generation
Zinc Toxicity: From “No, Never” to “Hardly Ever”
Volume 142, Issue 4, Pages (April 2012)
A Quantitative Model of Cortical Spreading Depression Due to Purinergic and Gap- Junction Transmission in Astrocyte Networks  Max R. Bennett, Les Farnell,
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Presentation transcript:

Molecular pathology of Wilson’s disease: A brief Vassiliki Lalioti, Ignacio Sandoval, Doris Cassio, Jean-Charles Duclos-Vallée  Journal of Hepatology  Volume 53, Issue 6, Pages 1151-1153 (December 2010) DOI: 10.1016/j.jhep.2010.07.008 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Cyclic phosphorylation–dephosphorylation of ATP7B and vectorial transport of Cu through the ion channel. Five Cu binding domains (CBD) are aligned along the N-cytoplasmic end of ATP7B. The chaperone Atox1 transfers Cu+ to the CBD2 [1]. The subsequent filling of CBDs1–4 with Cu+ provokes structural changes that facilitate the binding of ATP to the N-site [2], bringing bound ATP in close proximity to the phosphorylation site [3] and facilitating the binding of a Cu+ atom by the two juxtaposed Cys in the plane of the transmembrane domains TM1 and TM2 [3]. Next, filling of CBDs5 and 6 with Cu+ favours the transfer of a Cu+ atom to the CPC motif in TM6 [3]. Phosphorylation of the Asp residue in the P-site [4] closes the access to the ion channel from the cytoplasm and facilitates the reception of the translocated Cu+ by the exofacial vestibule. Cu+ is then released at the opposite side of the membrane and dephosphorylation of Asp-P by the phosphatase in the A-site [5] completes the phospho-dephosphorylation cycle [6] and resets the channel to basal conditions. (B) Point mutations (G85V, R778L, H1069Q, C1104F, V1262F, G1341V, S1363F) changes the levels, cellular distribution, and activity of ATP7B and results in Wilson disease (WD). (C) At physiological concentrations of Cu in the hepatocyte, ATP7B transfers the Cu+ donated by Atox1 to the newly synthesized cuproproteins (i.e. ceruloplasmin, CP) moving through the trans-Golgi network (TGN). The increase in Cu concentration beyond physiological levels in the hepatocyte provokes the bulk translocation of ATP7B from the TGN to the membrane of the bile canaliculi where it mediates the elimination of excess Cu into the bile. Restoration of the physiological levels of Cu results in recycling of ATP7B to the TGN; TJ: Tight junction, SA: serum albumin. (D) Elimination of Cu by the hepatocyte into the bile is decreased in WD patients as compared to healthy individuals (N), causing Cu toxicosis. The main targets of toxic Cu are the brain and liver. Low resorption of Cu in the kidney results in high levels of Cu in the urine. The volume of Cu flow into organs and body fluids is indicated by the arrow size. Journal of Hepatology 2010 53, 1151-1153DOI: (10.1016/j.jhep.2010.07.008) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions